17,261 trials
Infections, Meningococcal
Primary: Percentages of Subjects With hSBA Titers ≥LLOQ Against 4 Serogroup B Test Strains, and Against N. Meningitidis Serogroups A, C, W and Y at 24 Months After Last…
Critical Illness
Primary: Plasma Zinc Concentration Over Time — 51.2; 36.4; 37.7; 43.4 mcg/dL
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0 percentage of participants
Rh Disease
Primary: CL/F : Apparent Clearance — 0.0106 L/h
Pain, Postoperative
Primary: Cumulative Narcotic Use — 27; 45 mg — p=0.006
Age Related Macular Degeneration
Primary: Best-corrected Visual Acuity — 52.9 ETDRS letters
Primary Sjögren's Syndrome
Primary: Change From Baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) — 12.0; 11.8; 10.6; 11.0 units on a scale — p=0.397
Mucositis
Primary: Adherence to Treatment — 4; 1 Participants
Breast Cancer
Primary: Progression-Free Survival (PFS) — 22.1; 7.3; 19.0 Weeks — p=0.1315
Eosinophilic Esophagitis
Primary: Number of Participants With Improvement of Espohageal Eosinophilia — 13; 0 Participants
Breast Cancer
Primary: Quality of Recovery Score — 165; 169 score on a scale
Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 4 Participants
Alzheimer's Disease
Primary: Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging — -0.06; -0.05 umol/100g/min (change)
Pneumococcal Infections
Primary: Percentage of Participants With an Adverse Event (AE) — 68.5; 64.3 Percentage of Participants
Recessive Dystrophic Epidermolysis Bullosa
Primary: Restoration of Full-length Type VII Collagen as Assessed by Immunofluorescence. — 5; 5; 4; 4 Fluorescence Intensity (MFI) for C7